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Abstract
Conjugated linoleic acid (CLA), a naturally occurring anticarcinogen found in dairy products, is an
intermediary product of ruminal biohydrogenation of polyunsaturated fatty acids. Few data exist
on the CLA content of the human blood plasma. The determination of a "normal" content could
help in estimating if a person consumes satisfactory amounts of CLA with the diet and thus takes
advantage of its potential beneficial effects on health. The purpose of this study was to compare the
plasma CLA content of individuals not consuming dairy products (group 1, n = 12), individuals
consuming normal amounts of dairy products (group 2, n = 77) and individuals consuming CLA
supplement (group 3, n = 12). The only CLA isomer that presented higher percentage than the
detection limit (0.03% of total fatty acids) was rumenic acid (cis9, trans11-octadecadienoic acid).
An interesting finding is that compared to the other two groups, group 3 members show the
highest average plasma content in rumenic acid, i.e. 0.20% of total fatty acids. The present study
could be characterized as the first step in the direction of establishing a normal CLA content of
human plasma. Based on these results, it could be suggested that the lower limit of the plasma CLA
content is approximately 0.1% of total fatty acids.
Background
Conjugated linoleic acid (CLA) is a term that refers to a
group of linoleic acid isomers with conjugated double
bonds. In the past two decades there has been an increas-
ing interest in the biological effects of CLA, since Grimm
and Pariza [1] reported that dienes in fried ground beef
protect against chemically induced cancer. The double
bonds of the various CLA isomers could be in positions 7,
9; 8, 10; 9, 11; 10,12; or 11, 13 with cis or trans configura-
tion, but the most abundant isomer in nature is cis-9,
trans-11 [2,3]. This isomer is called rumenic acid and is
formed by the anaerobic bacteria Butyrivibrio fibrisolvens in
the rumen [4,5].
The richest food sources of CLA are first the dairy prod-
ucts, especially cheese and then ruminant meat [6,7]. CLA
isomers can also be produced by heating linoleic acid in
the presence of alkaline solutions. The isomerisation of
linoleic acid to conjugated dienes was initially reported by
von Mikusch [8].
Several animal experiments relate the consumption of
CLA to the inhibition of tumorgenesis [9-11] and athero-
genesis [12-14], the normalizing of glucose tolerance
[15], and the reduction of body fat [16-18]. In several
nutritional studies the effect of CLA supplementation on
human body composition has been studied. However, the
results of these studies showed that CLA had less effect on
body fat than it was concluded from in vivo studies. A
recent meta-analysis [19] has concluded that a dose of 3.2
g CLA/d produced a modest reduction in fat mass in
humans.
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It is known that rumenic acid is normally found in human
plasma as part of triglycerides, phospholipids and choles-
terol esters [20]. However, few data exist concerning the
normal concentrations of CLA in human plasma. This
kind of information could help to estimate if a person
takes satisfactory amounts of CLA with the diet or if there
is a need to increase them by supplementation, given its
potential effects on health-related parameters.
Mougios et al [21] showed that diet supplementation with
small doses of CLA in encapsulated form for 4–8 weeks,
may increase the CLA content in human serum. There is
no indication if this increase is within the normal levels of
a person consuming dairy. Therefore, in the present study,
an effort was made to set a "limit" between low and high
plasma CLA content. In this direction the plasma fatty
acid composition was determined in 101 volunteers
divided into three groups: a group not consuming any
dairy products, a group consuming normal amounts of
dairy products and a group consuming CLA supplements
for several months.
Materials and methods
Participants
Group 1 is comprised of 6 women and 6 men.
Group 2 is comprised of 37 women and 40 men.
Group 3 is comprised of 6 women and 6 men.
Blood samples used in the current study were collected
from German volunteers. The age of the volunteers ranged
from 18 to 65 years. Individuals were not affected by gas-
trointenstinal or liver diseases, which could influence
fatty acid metabolism. All participants were interviewed
about their dietary habits and especially about the con-
sumption of milk, cheese and other dairy products.
Another 12 volunteers were invited to participate in the
study, as they were daily consuming 4 × 500 mg soft gela-
tin capsules of CLA (CLA 70-Trofocell™, Trofocell™ Ltd,
Hamburg, Germany) for a period of 6 months. This Tro-
focell supplement contains about 35% of cis9, trans11-
octadecadienoic acid (rumenic acid) and an equal
amount of trans-10, cis-12-octadecadienoic acid.
Sample preparation
8–10 mL of venous blood samples were collected in
heparin tubes. After centrifugation at 4000 rpm the super-
natant blood plasma was separated with a pipette. The
blood samples were collected in the morning in the fasted
state after a 12 h restriction for meal and drinks.
Preparation and analysis of fatty acid methylesters
To 1 g of plasma, 5 mL n-KOH solution in 90% watery
methanol and 0,20 mg heptadecanoic acid methyl ester
internal standard in 1 mL hexane were added and the
solution was saponified at 4°C overnight. 15 mL of 10%
BF3 solution in methanol (BF3 methanolate, Merck) were
added and the solution was heated at 60°C for 15 min.
Then, it was extracted with 25 mL of hexane. The hexane
phase was evaporated in a rotary evaporator until dryness.
The residue was dissolved in 0.3 mL of hexane and ana-
lyzed with gas chromatography, according to Sagredos &
von Leitner [22].
In brief:
Gas chromatography – Conditions
Apparatus: HEWLETT-PACKARD Auto system; Column: Sil
88, 50 m, 0.25 ID, 0,25 μm Film thickness; Detector: FID
(300°C); Injection: 3 μL split 1 to 50 (250°C); Initial pres-
sure: 22 psi He; Temperature program: 60°C for 5 min iso-
therm, 5°C/min to 180°C, 16 min isotherm, 5°C/min to
220°C, 15 min isotherm.
The fatty acid methyl esters were identified by comparing
their retention times to those of standards. The CLA
methyl esters standards were obtained from Cayman
(Ann Arbor, Ml), while the other standards were obtained
from Sigma-Aldrich. The weight of CLA and that of the
other fatty acids were obtained from the chromatographs
and were transformed to weight percentages (%) of total
fatty acids in comparison to internal standard and by uti-
lizing response factors. The quantification limit was
0.03% of total fatty acids. Conventional statistics routines
(i.e. Excel spreadsheets) were employed for the statistical
analysis.
Results and discussion
The plasma fatty acid composition of the three participat-
ing groups examined.
Group 1
It comprises 12 individuals, who did not consume any
dairy products.
Group 2
In this group 77 volunteers were participated, who con-
sumed normal amounts of dairy products. It means a con-
sumption of about 300–400 g cheese/week. Cheese is the
CLA richest dairy product and the main nutriment for a
CLA intake. The weekly intake of milk or other dairy prod-
ucts has not been considered because of their relative low
concentrations of CLA [23].
Group 3
It comprises 12 participants, who daily, after lunch or din-
ner, were supplied with 4 × 500 mg CLA Capsules of a
total amount of 1.4 g CLA (= 0.7 g rumenic acid and 0.7 g
t10, c12-CLA).Lipids in Health and Disease 2008, 7:34 http://www.lipidworld.com/content/7/1/34
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The analytical results are summarized in Tables 1, 2 and 3
respectively. In all samples analyzed only the cis-9, trans-
11 isomer of CLA was found in amounts higher than the
detection limit. The rumenic acid content of group 1
ranged from 0.05 to 0.09% and averaged 0.08% of total
fatty acids. The rumenic acid content of group 2 ranged
from 0.05 to 0.33% and averaged 0.14% of total fatty
acids, significantly higher than the rumenic acid content
of group 1 samples. Finally, the rumenic acid content of
group 3 ranged from 0.16 to 0.25% with an average of
0.20% of total fatty acids, significantly higher than the
rumenic acid content of the two others groups. The distri-
bution of the rumenic acid values among the three groups
of individuals is presented in Figure 1. An interesting find-
ing is that only 15 of the 77 samples of the second group
present rumenic acid content comparable to the first
group. Group 1 exhibits an average plasma content in
rumenic acid of 0.08% of total fatty acids, significantly
lower than of group 2, i.e. 0.14% of total fatty acids. It is
noteworthy, that group 3 exhibits the highest average
plasma content in rumenic acid, i.e. 0.20% of total fatty
acids.
These results suggest that the main source of CLA in the
diet is milk and dairy products. Also, this finding is in
agreement with studies, which revealed that dairy prod-
ucts, especially cheeses due to their high fat content, are
rich CLA sources [6,7,23]. On the other hand, 32 of the 77
samples of the second group presented amounts equal to
or higher than the lower limit of the third group (supple-
mentation group). The others show lower levels than the
lower CLA level of the supplementation group. These data
indicate that the supplementation can increase the CLA
content of the human blood plasma and is therefore an
alternative source of CLA for people who suffer from dairy
allergies or do not consume dairy products for other rea-
sons. These results comply with previous ones presented
by Mougios et al [21].
Table 1: Blood plasma fatty acid composition (% of total fatty acids) of individuals not consuming dairy products (n = 12) (group 1)
Fatty acid Occurrence of value (>0.03%) Median Average Standard Deviation Minimum Maximum
C 12:0 12 0.12 0.13 0.09 0.05 0.38
C 14:0 12 1.05 1.11 0.56 0.49 2.60
C 14:1ω5 12 0.08 0.09 0.05 0.03 0.21
C 15:0 12 0.22 0.26 0.09 0.17 0.50
C 16:0 12 23.3 23.39 2.70 18.5 27.70
C 16:1ω7 t 12 0.20 0.21 0.07 0.08 0.40
C 16:1ω9 c 12 0.31 0.32 0.09 0.21 0.48
C 16:1ω7 c 12 2.10 1.94 0.79 0.87 3.30
C 17:1ω7 7 0.14 0.13 0.04 0.07 0.17
C 18:0 12 8.40 8.13 1.18 5.80 10.2
C 18:1ω9 t 12 0.32 0.30 0.06 0.16 0.37
C 18:1ω7 t 9 0.31 0.32 0.12 0.13 0.58
C 18:1ω9 c 12 16.85 18.23 3.00 15.00 24.50
C 18:1ω7 c 12 1.40 1.50 0.32 1.10 2.20
C 18:1ω6 c 12 0.13 0.14 0.04 0.08 0.23
C 18:2ω6 tt 10 0.08 0.08 0.04 0.03 0.17
C 18:2ω6 ct 12 0.17 0.19 0.04 0.14 0.28
C 18:2ω6 tc 12 0.14 0.14 0.04 0.09 0.23
C 18:2ω6 cc 12 25.75 25.23 4.96 16.9 32.1
C 20:0 9 0.06 0.07 0.02 0.04 0.12
C 18:3ω6 12 0.39 0.34 0.12 0.12 0.50
C 20:1ω9 12 0.13 0.17 0.09 0.09 0.42
C 18:3ω3 12 0.51 0.54 0.21 0.33 1.00
c9, t11-CLA 12 0.08 0.08 0.01 0.05 0.09
t10, c12-CLA <0.03 <0.03
C 18:4ω3 3 0.24 0.24 0.02 0.21 0.26
C 20:2ω6 12 0.23 0.22 0.02 0.17 0.25
C 22:0 11 0.15 0.16 0.05 0.08 0.25
C 20:3ω6 12 1.35 1.39 0.23 0.96 1.80
C 20:4ω6 12 7.20 6.83 1.57 4.00 9.20
C 20:5ω3 (EPA) 12 0.81 0.88 0.35 0.17 1.50
C 22:4ω6 12 0.22 0.22 0.05 0.11 0.33
C 22:5ω3 (DPA) 12 0.65 0.67 0.15 0.42 1.00
C 22:6ω3 (DHA) 12 2.40 2.55 0.85 1.20 4.30
Total fatty acids ( μg/g) 12 2464 2581 669 1483 3948Lipids in Health and Disease 2008, 7:34 http://www.lipidworld.com/content/7/1/34
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It was additionally of interest to find out, if the CLA sup-
plementation has an influence on the composition of the
total amount of saturated and unsaturated fatty acids and
on the ratio of ω-6- to ω-3-fatty acids in the blood plasma.
The corresponded comparison data of the three groups
were calculated from the tables 1, 2 and 3 and are
expressed as % the total fatty acids (Table 4). The CLA sup-
plementation shows obvious a significantly effect on the
total saturated fatty acids and the ω-6-fatty acids. CLA
reduces the total saturated fatty acids as well as the total ω-
6-fatty acids and especially the arachidonic acid. This cor-
responds to a reduction of the ratio of ω-6-fatty acids and
arachidonic acid to ω-3-fatty acids. CLA appears to react as
antagonist against ω-6-fatty acids and arachidonic acid.
The last is of importance, because a low ratio of ω-6- to ω-
3-fatty acids is a valuable determinant of health [22,24].
These effects of CLA on saturated acids and ω-6-fatty acids
have to be confirm through further studies with a higher
number of test persons.
The present study could be characterized as a first step in
the direction of establishing a normal CLA content of
human blood plasma. Based on these results, it could be
suggested that the lower limit of the blood plasma CLA
content is approximately 0.1% of total fatty acids. Thus,
individuals who present rumenic acid levels within the
range of the first group, namely up to 0,09% of total fatty
acids, should consider increasing their CLA uptake
through dairy products and/or supplements and could
serve as ideal participants in future CLA supplementation
studies.
Table 2: Blood plasma fatty acid composition (% of total fatty acids) of individuals consuming normal amounts of dairy products (n = 
77) (group 2)
Fatty acid Occurrence of value (>0.03%) Median Average Standard Deviation Minimum Maximum
C 12:0 76 0.19 0.22 0.13 0.07 0.74
C 14:0 77 1.40 1.50 0.64 0.49 3.30
C 14:1ω5 76 0.10 0.12 0.07 0.03 0.35
C 15:0 77 0.33 0.33 0.11 0.13 0.77
C 16:0 77 24.40 24.34 2.63 17.00 29.90
C 16:1ω7 t 77 0.23 0.23 0.08 0.05 0.43
C 16:1ω9 c 76 0.36 0.36 0.11 0.07 0.88
C 16:1ω7 c 77 2.00 2.15 0.89 0.36 4.70
C 17:1ω7 57 0.17 0.16 0.06 0.03 0.30
C 18:0 77 7.60 7.78 1.11 5.20 11.9
C 18:1ω9 t 70 0.355 0.37 0.17 0.13 1.30
C 18:1ω7 t 58 0.32 0.34 0.13 0.06 0.64
C 18:1ω9 c 77 19.3 19.44 3.10 11.6 28.2
C 18:1ω7 c 77 1.50 1.51 0.34 0.92 2.80
C 18:1ω6 c 59 0.10 0.11 0.04 0.03 0.18
C 18:2ω6 tt 72 0.08 0.09 0.05 0.03 0.23
C 18:2ω6 ct 77 0.19 0.20 0.05 0.12 0.33
C 18:2ω6 tc 77 0.14 0.15 0.04 0.08 0.28
C 18:2ω6 cc 77 24.20 24.81 5.01 14.20 37.40
C 20:0 74 0.06 0.08 0.05 0.02 0.24
C 18:3ω6 77 0.29 0.30 0.11 0.08 0.83
C 20:1ω9 77 0.15 0.15 0.05 0.06 0.30
C 18:3ω3 77 0.50 0.59 0.41 0.25 3.30
c9, t11-CLA 77 0.14 0.14 0.05 0.05 0.33
t10, c12-CLA <0.03 <0.03
C 18:4ω3 15 0.12 0.14 0.07 0.06 0.35
C 20:2ω6 77 0.22 0.22 0.05 0.13 0.40
C 22:0 74 0.15 0.16 0.06 0.04 0.34
C 20:3ω6 77 1.40 1.39 0.34 0.57 2.30
C 22:1ω11 2 0.035 0.04 0.01 0.03 0.04
C 20:4ω6 77 5.30 5.41 1.43 2.50 9.10
C 20:5ω3 77 0.64 0.75 0.44 0.19 2.50
C 22:4ω6 76 0.19 0.19 0.06 0.04 0.41
C 22:5ω3 77 0.52 0.56 0.16 0.34 1.10
C 22:6ω3 77 1.80 1.91 0.77 0.70 4.30
Total fatty acids ( μg/g) 77 2553 2834 890 1438 6093Lipids in Health and Disease 2008, 7:34 http://www.lipidworld.com/content/7/1/34
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Table 3: Blood plasma fatty acid composition (% of total fatty acids) of individuals consuming CLA supplements*) (n = 12) (group 3)
Fatty acid Occurrence of value (>0.03%) Median Average Standard Deviation Minimum Maximum
C 12:0 7 0.20 0.25 0.10 0.14 0.39
C 14:0 12 1.80 1.72 0.73 0.55 2.70
C 14:1ω5 4 0.20 0.15 0.09 0.04 0.27
C 15:0 12 0.39 0.42 0.20 0.18 0.77
C 16:0 12 25.40 25.53 1.72 22.50 28.80
C 16:1ω7 t 12 0.20 0.22 0.12 0.05 0.38
C 16:1ω9 c 12 0.42 0.42 0.23 0.07 0.88
C 16:1ω7 c 12 2.60 2.57 1.13 4.70 0.66
C 17:1ω7 11 0.19 0.18 0.08 0.07 0.27
C 18:0 12 6.70 6.01 1.08 5.90 9.20
C 18:1ω9 t 12 0.45 0.43 0.16 0.17 0.69
C 18:1ω7 t 6 0.17 0.26 0.16 0.13 0.49
C 18:1ω9 c 12 20.30 19.99 2.29 15.50 23.50
C 18:1ω7 c 12 1.50 1.61 0.40 1.10 2.20
C 18:1ω6 c 8 0.11 0.12 0.03 0.08 0.16
C 18:1ω6 tt 12 0.11 0.11 0.06 0.04 0.21
C 18:2ω6 ct 12 0.20 0.22 0.07 0.14 0.33
C 18:2ω6 tc 12 0.16 0.17 0.06 0.09 0.28
C 18:2ω6 cc 12 21.00 22.34 6.32 14.20 34.5
C 20:0 12 0.04 0.06 0.03 0.03 0.13
C 18:3ω6 12 0.30 0.33 0.11 0.17 0.49
C 20:1ω9 12 0.14 0.15 0.03 0.10 0.19
C 18:3ω3 12 0.53 0.89 0.99 0.36 3.30
c9, t11-CLA 12 0.19 0.20 0.02 0.16 0.25
t10, c12-CLA 12 <0.03 <0.03
C 18:4ω3 4 0.13 0.13 0.04 0.09 0.17
C 20:2ω6 12 0.19 0.19 0.02 0.17 0.24
C 22:0 11 0.13 0.12 0.05 0.04 0.19
C 20:3ω6 12 1.30 1.27 0.20 0.86 1.50
C 20:4ω6 12 4.30 4.11 0.95 2.50 5.30
C 20:5ω3 (EPA) 12 0.75 1.12 0.72 0.29 2.50
C 22:4ω6 12 0.19 0.17 0.08 0.04 0.28
C 22:5ω3 (DPA) 12 0.56 0.60 0.19 0.38 0.96
C 22:6ω3 (DHA) 12 1.40 1.93 1.19 0.83 4.30
Total fatty acids ( μg/g) 12 2571 2778 573 2111 3918
*) The daily supplementation was 4 × 500 mg CLA Capsules with a total amount of about 700 mg c9, t11-CLA and 700 mg t10, c12-CLA.
Distribution of the CLA values among the three groups of individuals Figure 1
Distribution of the CLA values among the three groups of individuals.
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